The Evolving Treatment Landscape of Small Cell Lung Cancer
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: Overview of SCLC and Importance of Early Diagnosis By Charu Aggarwal, MD, MPH, Taofeek K. Owonikoko, MD, PhD, Charles M. Rudin, MD, PhD, Vivek Subbiah, MD, Jared Weiss, MD Drs Owonikoko and Weiss provide a brief overview of small cell lung cancer and the vital importance of an early diagnosis to improve patient outcomes.
EP. 2: Use of the TNM Staging System in SCLC By Charu Aggarwal, MD, MPH, Taofeek K. Owonikoko, MD, PhD, Charles M. Rudin, MD, PhD, Vivek Subbiah, MD, Jared Weiss, MD Charles Rudin, MD, PhD, explains the prognostic staging systems used for small cell lung cancer.
EP. 3: Progress in the Treatment and Management of SCLC By Charu Aggarwal, MD, MPH, Taofeek K. Owonikoko, MD, PhD, Charles M. Rudin, MD, PhD, Vivek Subbiah, MD, Jared Weiss, MD The panel discusses how the field of small cell lung cancer treatment has changed in recent years.
EP. 4: Patient Profile 1: A 68-Year-Old Male with SCLC and Brain Metastases By Charu Aggarwal, MD, MPH, Taofeek K. Owonikoko, MD, PhD, Charles M. Rudin, MD, PhD, Vivek Subbiah, MD, Jared Weiss, MD Charu Aggarwal, MD, MPH, presents the profile of a patient with small cell lung cancer with brain metastases to spark a discussion on treatment approaches in the frontline setting.
EP. 5: Frontline Therapy for SCLC: The CASPIAN Trial of Durvalumab + Chemotherapy By Taofeek K. Owonikoko, MD, PhD, Charu Aggarwal, MD, MPH, Charles M. Rudin, MD, PhD, Vivek Subbiah, MD, Jared Weiss, MD Jared Weiss, MD, reviews data from the CASPIAN trial of durvalumab plus chemotherapy in patients with extensive-stage small cell lung cancer.
EP. 6: Management of Adverse Events Associated with Durvalumab + Chemotherapy By Charu Aggarwal, MD, MPH, Taofeek K. Owonikoko, MD, PhD, Charles M. Rudin, MD, Vivek Subbiah, MD, Jared Weiss, MD Vivek Subbiah, MD, analyzes adverse events observed with durvalumab plus chemotherapy in patients with SCLC and how they can be managed.
EP. 7: IMpower 133 Trial and Patient Selection for Durvalumab + Chemotherapy vs Atezolizumab + Chemotherapy By Charu Aggarwal, MD, MPH, Taofeek K. Owonikoko, MD, PhD, Charles M. Rudin, MD, PhD, Vivek Subbiah, MD, Jared Weiss, MD Dr Charu Aggarwal shares data from the IMpower133 trial of atezolizumab plus chemotherapy for SCLC, and how to select the appropriate frontline therapy.
EP. 8: Ongoing Trials and Real-World Studies in Frontline SCLC By Charu Aggarwal, MD, MPH, Taofeek K. Owonikoko, MD, PhD, Charles M. Rudin, MD, PhD, Vivek Subbiah, MD, Jared Weiss, MD Dr Charles Rudin highlights other notable clinical trials and real-world studies in patients with SCLC in the frontline setting.
EP. 9: Patient Profile 2: A 60-Year-Old Man with SCLC Progressing on First-Line Therapy By Charu Aggarwal, MD, MPH, Taofeek K. Owonikoko, MD, PhD, Charles M. Rudin, MD, PhD, Vivek Subbiah, MD, Jared Weiss, MD Vivek Subbiah, MD, MPH, presents the patient profile of a 60-year-old man with SCLC who progressed on frontline therapy.
EP. 10: Second Line Treatment Options in SCLC and Selecting the Appropriate Therapy By Charu Aggarwal, MD, MPH, Taofeek K. Owonikoko, MD, PhD, Charles M. Rudin, MD, PhD, Vivek Subbiah, MD, Jared Weiss, MD The panel discusses the second line treatment options in SCLC and how they choose among the various options based on patient and disease characteristics.
EP. 11: Lurbinectedin for SCLC Treatment in the Second-Line Setting By Charu Aggarwal, MD, MPH, Taofeek K. Owonikoko, MD, PhD, Charles M. Rudin, MD, Vivek Subbiah, MD, Jared Weiss, MD Dr Vivek Subbiah explains the clinical trial data that led to the approval of lurbinectedin for SCLC treatment.
EP. 12: Patient Profile 3: A 70-Year-Old Man with SCLC Receiving Chemotherapy in the Second-Line Setting By Charu Aggarwal, MD, MPH, Taofeek K. Owonikoko, MD, PhD, Charles M. Rudin, MD, Vivek Subbiah, MD, Jared Weiss, MD Dr Jared Weiss presents the profile of a 70-year-old male patient with SCLC who received chemotherapy in the second line setting for discussion to the panel.
EP. 13: Choosing the Appropriate Treatment in the Second Line Setting in SCLC By Charu Aggarwal, MD, MPH, Taofeek K. Owonikoko, MD, PhD, Charles M. Rudin, MD, Vivek Subbiah, MD, Jared Weiss, MD Experts provide insights on choosing the optimal therapy in patients with small cell lung cancer in the second line and beyond.
EP. 14: Investigational Agents in SCLC in the Second Line Setting and Beyond By Charu Aggarwal, MD, MPH, Taofeek K. Owonikoko, MD, PhD, Charles M. Rudin, MD, Vivek Subbiah, MD, Jared Weiss, MD Taofeek Owonikoko, MD, PhD, highlights investigational agents and ongoing clinical trials in SCLC he looks forward to.
EP. 15: Clinical Practice Pearls and the Future of SCLC By Charu Aggarwal, MD, MPH, Taofeek K. Owonikoko, MD, PhD, Charles M. Rudin, MD, Vivek Subbiah, MD, Jared Weiss, MD The panel shares clinical pearls for community oncologists treating small cell lung cancer.
